Bayer gets EU backing to extend Eylea treatment gaps
Bayer secures EMA backing to extend Eylea injection intervals to six months, potentially outpacing Roche's Vabysmo. Final EU decision expected soon.
· 1 MIN READ
Topic
Bayer Pharmaceutical
Latest Daily Tribune news and analysis on Bayer Pharmaceutical.